| 0.9325 -0.088 (-8.58%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.29  |
1-year : | 1.43 |
| Resists | First : | 1.11 |
Second : | 1.22 |
| Pivot price | 1.01 |
|||
| Supports | First : | 0.92 |
Second : | 0.76 |
| MAs | MA(5) : | 0.98 |
MA(20) : | 1.04 |
| MA(100) : | 1.15 |
MA(250) : | 1.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.1 |
D(3) : | 21.6 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 3.06 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABVC ] has closed above bottom band by 7.4%. Bollinger Bands are 60.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.05 - 1.06 | 1.06 - 1.06 |
| Low: | 0.91 - 0.91 | 0.91 - 0.92 |
| Close: | 0.92 - 0.93 | 0.93 - 0.94 |
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Fri, 02 Oct 2026
ABVC Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 18 Aug 2026
ABVC BioPharma (ABVC) Slides 5.56% to $0.85 as Micro-Cap Biotech Faces Selling Pressure - Quality Factor - dars.gov.et
Sat, 15 Aug 2026
ABVC BioPharma (ABVC) Declines 6.2% to $0.90, Testing Key Support - High Conviction Picks - dars.gov.et
Tue, 04 Aug 2026
ABVC postpones BioKey share distribution; ratio, record date unchanged - TradingView
Fri, 24 Jul 2026
ABVC BioPharma Sheds 3.33% as Shares Test Key Support at $1.10 - Volatility Stop - www.dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 490 (K) |
| Shares Short P.Month | 525 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -69.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -3.11 |
| PEG Ratio | 0 |
| Price to Book value | 2.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|